Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.

Journal: European urology oncology
Published Date: Feb 1, 2021

Abstract

BACKGROUND: Owing to the large variation in treatment response among patients with high-risk prostate cancer, it would be of value to use objective tools to monitor the status of bone metastases during clinical trials. Automated Bone Scan Index (aBSI) based on artificial intelligence has been proposed as an imaging biomarker for the quantification of skeletal metastases from bone scintigraphy.

Authors

  • Mariana Reza
    Department of Clinical Physiology, Translational Medicine, Malmö, Lund University, Malmö, Sweden.
  • Manfred Wirth
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
  • Teuvo Tammela
    Department of Urology, Tampere University Hospital and University of Tampere, Tampere, Finland.
  • Virgilio Cicalese
    Department of Urology, Azienda Ospedaliera S. Giuseppe Moscati, Avellino, Italy.
  • Francisco Gomez Veiga
    Urology Department and Kidney Transplant Unit, Translational Research Group of Urology GITUR-IBSAL, Salamanca University Hospital, Salamanca, Spain.
  • Peter Mulders
    Department of Urology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Kurt Miller
    Department of Urology, Charité, Universitätsmedizin, Berlin, Germany.
  • Andrea Tubaro
    Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
  • Frans Debruyne
    Department of Urology, Andros Clinic, Arnhem, The Netherlands.
  • Anup Patel
    London, UK.
  • Christien Caris
    European Association of Urology, Research Foundation (EAU RF), Arnhem, The Netherlands.
  • Wim Witjes
    European Association of Urology, Research Foundation (EAU RF), Arnhem, The Netherlands.
  • Ola Thorsson
    Department of Clinical Physiology, Translational Medicine, Malmö, Lund University, Malmö, Sweden.
  • Per Wollmer
    Department of Clinical Physiology, Translational Medicine, Malmö, Lund University, Malmö, Sweden.
  • Lars Edenbrandt
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Mattias Ohlsson
    Department of Astronomy and Theoretical Physics, Lund University, Lund, Sweden.
  • Elin Trägårdh
    Department of Clinical Physiology and Nuclear Medicine, Lund University and Skåne University Hospital, Malmö, Sweden.
  • Anders Bjartell
    Department of Urology, Skåne University Hospital, Lund University, Lund, Sweden.

Keywords

External Resources

Popular Topics
Recent Journals